Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Peiyu Xing, Bo Meng, Xiaojia Hu, Wei Qu & Shaowei Wang. (2023) Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab. Clinical Ophthalmology 17, pages 3491-3497.
Read now
Read now
Stella X. Chen, Charlotte Greif, Ruby S. Gibson, Martina L. Porter & Alexa B. Kimball. (2022) Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opinion on Pharmacotherapy 23:8, pages 959-978.
Read now
Read now
Moein Ebrahimi, Maryam Balibegloo & Nima Rezaei. (2022) Monoclonal antibodies in diabetic retinopathy. Expert Review of Clinical Immunology 18:2, pages 163-178.
Read now
Read now
Burak Erdem & Mustafa Gok. (2021) Evaluation of the Effects of Intravitreal Aflibercept and Ranibizumab on Systemic Inflammatory and Cardiovascular Biomarkers in Patients with Neovascular Age-related Macular Degeneration. Current Eye Research 46:9, pages 1387-1392.
Read now
Read now
Mesha Saeed, Sara Zalba, Ann L B Seynhaeve, Reno Debets & Timo L M ten Hagen. (2019) Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response. International Journal of Nanomedicine 14, pages 2069-2089.
Read now
Read now
Antonio da Silva, Ulrich Kronthaler, Vera Koppenburg, Martin Fink, Ines Meyer, Anastassia Papandrikopoulou, Matthias Hofmann, Thomas Stangler & Jan Visser. (2014) Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leukemia & Lymphoma 55:7, pages 1609-1617.
Read now
Read now
Tadeusz Robak, Pawel Robak & Piotr Smolewski. (2012) The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 1-16.
Read now
Read now
Jasmine P. Davda & Ryan J. Hansen. (2010) Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. mAbs 2:5, pages 576-588.
Read now
Read now
WW Cheng & TM Allen. (2010) The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opinion on Drug Delivery 7:4, pages 461-478.
Read now
Read now
Haritha Samaranayake, Thomas Wirth, Diana Schenkwein, Jani K. Räty & Seppo Ylä-Herttuala. (2009) Challenges in monoclonal antibody-based therapies. Annals of Medicine 41:5, pages 322-331.
Read now
Read now
Articles from other publishers (88)
João Vito Barroso de Freitas, Alice Vitoria Frota Reis, Alan Denis Olivindo Silva, Ana Carolina Cruz de Sousa, Jéssica Roberta Pereira Martins, Karina Alexandre Barros Nogueira, Thais da Silva Moreira, Raquel Petrilli & Josimar O. Eloy. 2023. Cancer Nanotechnology. Cancer Nanotechnology
115
176
.
Yong Cheng, Shuang Sun, Xun Deng, Xuemei Zhu, Dandan Linghu, Xiantao Sun & Jianhong Liang. (2022) Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity. British Journal of Ophthalmology 106:9, pages 1295-1300.
Crossref
Crossref
Utku Furuncuoglu, Aslı Vural, Alev Kural, Ismail Umut Onur & Fadime Ulviye Yigit. (2022) Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity. Japanese Journal of Ophthalmology 66:2, pages 151-158.
Crossref
Crossref
Christopher M. Gromisch, Glaiza L. A. Tan, Khristine Amber Pasion, Ann-Marie Moran, Matthew S. Gromisch, Mark W. Grinstaff, Francis J. Carr, Victoria L. M. Herrera & Nelson Ruiz-Opazo. (2021) Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu/nu model. BMC Cancer 21:1.
Crossref
Crossref
Silvia Peña-Cabia, Ana Royuela Vicente, Ruth Ramos Díaz, Fernando Gutiérrez Nicolás, Ángela Peñalver Vera, Isabel Siso García, Ricardo Hitt Sabag, Concepción García Lacalle, Ana Peña-Cabia, Irene Iglesias-Peinado, Benito García Díaz & Ana López-Martín. (2021) Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer. Biomedicine & Pharmacotherapy 141, pages 111827.
Crossref
Crossref
Carla F.C. Fernandes, Soraya S. Pereira, Marcos B. Luiz, Nauanny K.R.L. Silva, Marcela Cristina S. Silva, Anna Carolina M. Marinho, Marcela H.G. Fonseca, Gilvan Pessoa Furtado, Raphael Trevizani, Roberto Nicolete, Andreimar M. Soares, Juliana P. Zuliani & Rodrigo G. Stabeli. (2021) Engineering of single-domain antibodies for next-generation snakebite antivenoms. International Journal of Biological Macromolecules 185, pages 240-250.
Crossref
Crossref
Nazife Aşikgarip & Nursal Melda Yenerel. (2021) Comparison of the effects of intravitreal ranibizumab and aflibercept on retinal vessel diameters in patients with diabetic macular edema. Photodiagnosis and Photodynamic Therapy 34, pages 102282.
Crossref
Crossref
Céline Desvignes, David Ternant, Thierry Lecomte, Astrid Lièvre, Marc Ohresser, Romain Chautard, William Raoul & Gilles Paintaud. (2021) A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. Bioanalysis 13:7, pages 565-574.
Crossref
Crossref
Vishakha Tambe, Havish Shukla, Kuldeep Rajpoot, Murali Monohar Pandey & Rakesh Kumar Tekade. 2021. Biopharmaceutics and Pharmacokinetics Considerations. Biopharmaceutics and Pharmacokinetics Considerations
539
565
.
Amina Bensalem & David Ternant. (2020) Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clinical Pharmacokinetics 59:7, pages 857-874.
Crossref
Crossref
David Ternant & Stéphanie Chhun. (2020) Variabilité pharmacocinétique des anticorps thérapeutiques. médecine/sciences 35:12, pages 1130-1136.
Crossref
Crossref
Samir M. El-Baha, Ahmed M. Abdel Hadi & Mahmoud A. Abouhussein. (2019) Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema. Journal of Ophthalmology 2019, pages 1-5.
Crossref
Crossref
Ahmed A. Suleiman, Mukul Minocha, Amit Khatri, Yinuo Pang & Ahmed A. Othman. (2019) Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials. Clinical Pharmacokinetics 58:10, pages 1309-1321.
Crossref
Crossref
Rajesh Kumar, Hilal Ahmed Parray, Tripti Shrivastava, Subrata Sinha & Kalpana Luthra. (2019) Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies. International Journal of Biological Macromolecules 135, pages 907-918.
Crossref
Crossref
Xuting Chen, Lin Zhou, Qi Zhang, Yu Xu, Peiquan Zhao & Hongping Xia. (2019) Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity. Journal of Ophthalmology 2019, pages 1-6.
Crossref
Crossref
David Ternant, Nicolas Azzopardi, William Raoul, Theodora Bejan-Angoulvant & Gilles Paintaud. (2018) Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clinical Pharmacokinetics 58:2, pages 169-187.
Crossref
Crossref
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung & Sandhya Girish. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
151
190
.
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
Crossref
Amy Hemperly & Niels Vande Casteele. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:8, pages 929-942.
Crossref
Crossref
Erika Cecchin, Elena De Mattia, Fabrizio Ecca & Giuseppe Toffoli. (2018) Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resistance Updates 39, pages 18-40.
Crossref
Crossref
Chung-Ying Huang, Reyin Lien, Nan-Kai Wang, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang, Chi-Chun Lai & Wei-Chi Wu. (2017) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefe's Archive for Clinical and Experimental Ophthalmology 256:3, pages 479-487.
Crossref
Crossref
Rosa Bustos, Carlos Zapata, Efraín Esteban, Julio-César García, Edwin Jáuregui & Diego Jaimes. (2018) Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor. Sensors 18:3, pages 691.
Crossref
Crossref
Zheng Lu, Jennifer Sheng & Wenhui Zhang. 2017. Protein Therapeutics. Protein Therapeutics
311
340
.
Robert L. Avery, Alessandro A. Castellarin, Nathan C. Steinle, Dilsher S. Dhoot, Dante J. Pieramici, Robert See, Stephen Couvillion, Ma'an A. Nasir, Melvin D. Rabena, Mauricio MaiaSherri Van EverenKha LeWilliam D. Hanley. (2017) SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina 37:10, pages 1847-1858.
Crossref
Crossref
Johannes Gojo, Robert Sauermann, Ursula Knaack, Irene Slavc & Andreas Peyrl. (2017) Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs in R&D 17:3, pages 469-474.
Crossref
Crossref
Gilles PaintaudChristophe PassotDavid TernantAntonio BertolottoTheodora Bejan-AngoulvantDora Pascual-Salcedo & Denis Mulleman. (2017) Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Therapeutic Drug Monitoring 39:4, pages 339-343.
Crossref
Crossref
Christophe PassotMieke F. Pouw, Denis MullemanTheodora Bejan-AngoulvantGilles PaintaudErwin DreesenDavid Ternant. (2017) Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic–Pharmacodynamic Modeling. Therapeutic Drug Monitoring 39:4, pages 322-326.
Crossref
Crossref
Tarianna Stewart, William T. Koval, Samuel A. Molina, Suzanne M. Bock, James W. LillardJr.Jr., Russell F. Ross, Tejal A. Desai & Michael Koval. (2017) Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway. Experimental Cell Research 355:2, pages 153-161.
Crossref
Crossref
Wei-Chi Wu, Chia-Pang Shih, Reyin Lien, Nan-Kai Wang, Yen-Po Chen, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang & Chi-Chun Lai. (2017) SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY. Retina 37:4, pages 694-701.
Crossref
Crossref
Daphne Bertholee, Jan Gerard Maring & André B. P. van Kuilenburg. (2016) Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clinical Pharmacokinetics 56:4, pages 317-337.
Crossref
Crossref
Cihan Ünlü, Gurkan Erdogan, Betul Onal Gunay, Esra Kardes, Betul Ilkay Sezgin Akcay & Ahmet Ergin. (2016) Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema. International Ophthalmology 37:1, pages 147-158.
Crossref
Crossref
K.B. Meyer-Tamaki. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
617
645
.
Masayuki Urabe, Tetsuo Ushiku, Yasuyuki Seto & Masashi Fukayama. (2016) Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy. American Journal of Surgical Pathology 40:10, pages 1326-1333.
Crossref
Crossref
Yoann Pointreau, Nicolas AzzopardiDavid TernantGilles Calais & Gilles Paintaud. (2016) Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. Therapeutic Drug Monitoring 38:5, pages 567-572.
Crossref
Crossref
Azadeh Haeri, Sara Zalba, Timo L.M. ten Hagen, Simin Dadashzadeh & Gerben A. Koning. (2016) EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery. Colloids and Surfaces B: Biointerfaces 146, pages 657-669.
Crossref
Crossref
Duo Liu, Yuyang Tian, Donglin Sun, Haiming Sun, Yan Jin & Mei Dong. (2016) The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Annals of Hematology 95:9, pages 1483-1490.
Crossref
Crossref
C. Fischer, K. Schäfer, T. Dschietzig & H. Hoerauf. (2016) Analyse kardiovaskulärer Erkrankungen nach der Upload-Phase mit intravitrealem Ranibizumab oder Bevacizumab bei Patienten mit exsudativer altersbedingter MakuladegenerationAnalysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration. Der Ophthalmologe 113:7, pages 589-595.
Crossref
Crossref
DR Mould, G D'Haens & RN Upton. (2016) Clinical Decision Support Tools: The Evolution of a Revolution. Clinical Pharmacology & Therapeutics 99:4, pages 405-418.
Crossref
Crossref
David Ternant, Theodora Bejan-Angoulvant, Christophe Passot, Denis Mulleman & Gilles Paintaud. (2015) Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clinical Pharmacokinetics 54:11, pages 1107-1123.
Crossref
Crossref
J-R Azanza, B Sádaba & A Gómez-Guiu. (2014) Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?. Journal of Oncology Pharmacy Practice 21:5, pages 370-376.
Crossref
Crossref
Stephen Silberstein, Robert Lenz & Cen Xu. (2015) Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache: The Journal of Head and Face Pain 55:8, pages 1171-1182.
Crossref
Crossref
Johannes Wohlrab. (2015) Pharmakokinetische Besonderheiten von therapeutischen Antikörpern. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 13:6, pages 530-534.
Crossref
Crossref
Johannes Wohlrab. (2015) Pharmacokinetic characteristics of therapeutic antibodies. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 13:6, pages 530-534.
Crossref
Crossref
Diane R. Mould & Marla C. Dubinsky. (2015) Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. The Journal of Clinical Pharmacology 55:S3, pages S51-S59.
Crossref
Crossref
Byron P. Vaughn, William J. Sandborn & Adam S. Cheifetz. (2015) Biologic Concentration Testing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref
Robert L Avery, Alessandro A Castellarin, Nathan C Steinle, Dilsher S Dhoot, Dante Joseph Pieramici, Robert See, Stephen Couvillion, Ma'an A Nasir, Melvin D Rabena, Kha Le, Mauricio Maia & Jennifer E Visich. (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology 98:12, pages 1636-1641.
Crossref
Crossref
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal & Alain Astier. (2014) Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer 50:12, pages 2020-2036.
Crossref
Crossref
Diane-Charlotte Imbs, Sylvie Négrier, Philippe Cassier, Antoine Hollebecque, Andrea Varga, Ellen Blanc, Thierry Lafont, Bernard Escudier, Jean-Charles Soria, David Pérol & Etienne Chatelut. (2014) Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemotherapy and Pharmacology 73:6, pages 1189-1196.
Crossref
Crossref
Yong Zhang, Danling Wang, Lorenzo de Lichtervelde, Sophie B. Sun, Vaughn V. Smider, Peter G. Schultz & Feng Wang. (2013) Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties. Angewandte Chemie International Edition 52:32, pages 8295-8298.
Crossref
Crossref
Yong Zhang, Danling Wang, Lorenzo de Lichtervelde, Sophie B. Sun, Vaughn V. Smider, Peter G. Schultz & Feng Wang. (2013) Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties. Angewandte Chemie 125:32, pages 8453-8456.
Crossref
Crossref
Jean W Lee. (2013) ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis 5:16, pages 2003-2014.
Crossref
Crossref
Regina Kurrasch, Judith C. Brown, Myron Chu, Jenny Craigen, Philip Overend, Bela Patel, Steven Wolfe & David J. Chang. (2013) Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. The Journal of Rheumatology 40:7, pages 1089-1096.
Crossref
Crossref
Alexander Eser, Christian Primas & Walter Reinisch. (2013) Drug monitoring of biologics in inflammatory bowel disease. Current Opinion in Gastroenterology 29:4, pages 391-396.
Crossref
Crossref
Fabrice André, Joseph Ciccolini, Jean-Philippe Spano, Frédérique Penault-Llorca, Nicolas Mounier, Gilles Freyer, Jean-Yves Blay & Gérard Milano. (2013) Personalized medicine in oncology: where have we come from and where are we going?. Pharmacogenomics 14:8, pages 931-939.
Crossref
Crossref
Miroslav Dostalek, Iain Gardner, Brian M. Gurbaxani, Rachel H. Rose & Manoranjenni Chetty. (2013) Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies. Clinical Pharmacokinetics 52:2, pages 83-124.
Crossref
Crossref
Melinda Marian & Wolfgang Seghezzi. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
97
137
.
Kathleen B. Meyer-Tamaki. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development
489
516
.
Olivier Bouché & Pierre Laurent-PuigN. Azzopardi, D. Ternant & G. Paintaud. 2013. Médecine personnalisée en cancérologie digestive. Médecine personnalisée en cancérologie digestive
275
285
.
John D. Davis, Rong Deng, C. Andrew Boswell, Yi Zhang, Jing Li, Paul Fielder, Amita Joshi & Saraswati Kenkare-Mitra. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
143
178
.
Bo GaoShang YeapArthur ClementsBavanthi BalakrishnarMark WongHoward Gurney. (2012) Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology 30:32, pages 4017-4025.
Crossref
Crossref
Daniela Bumbaca, C. Andrew Boswell, Paul J. Fielder & Leslie A. Khawli. (2012) Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics. The AAPS Journal 14:3, pages 554-558.
Crossref
Crossref
Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, Isabelle Boucot, Anne d’Andon, Françoise Grudé, Thierry Lecomte, Soyi Liu-Leage, Daniel Olive, Pascal Piedbois, Martine Pigeon, Jean-Louis Pinquier, Jean-François Prost, Gilles Thibault & Christian Vitzling. (2012) Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety. Therapies 67:4, pages 329-337.
Crossref
Crossref
Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, Isabelle Boucot, Anne d’Andon, Françoise Grudé, Thierry Lecomte, Soyi Liu-Leage, Daniel Olive, Pascal Piedbois, Martine Pigeon, Jean-Louis Pinquier, Jean-François Prost, Gilles Thibault & Christian Vitzling. (2012) Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme. Therapies 67:4, pages 319-327.
Crossref
Crossref
I Ordás, D R Mould, B G Feagan & W J Sandborn. (2012) Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. Clinical Pharmacology & Therapeutics 91:4, pages 635-646.
Crossref
Crossref
Leonid Kagan, Michael R. Turner, Sathy V. Balu-Iyer & Donald E. Mager. (2011) Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. Pharmaceutical Research 29:2, pages 490-499.
Crossref
Crossref
Victoria CH Su, Jennifer Harrison, Christin Rogers & Mary HH Ensom. (2012) Belatacept: A New Biologic and Its Role in Kidney Transplantation. Annals of Pharmacotherapy 46:1, pages 57-67.
Crossref
Crossref
Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, Alain Morel, Valérie Gouilleux-Gruart, Céline Vignault-Desvignes, Hervé Watier, Erick Gamelin & Gilles Paintaud. (2011) Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients. Clinical Cancer Research 17:19, pages 6329-6337.
Crossref
Crossref
Daniel L. Keene, Carole Legare, Elaine Taylor, Jim Gallivan, Gloria Mah Cawthorn & Duc Vu. (2014) Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 38:4, pages 565-571.
Crossref
Crossref
Jamie Campbell, David Lowe & Matthew A Sleeman. (2011) Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. British Journal of Pharmacology 162:7, pages 1470-1484.
Crossref
Crossref
Taketo Yamada. (2011) Therapeutic Monoclonal Antibodies. The Keio Journal of Medicine 60:2, pages 37-46.
Crossref
Crossref
Roland E. Kontermann. 2011. Bispecific Antibodies. Bispecific Antibodies
1
28
.
Oscar E. Della Pasqua. 2011. Clinical Trial Simulations. Clinical Trial Simulations
281
306
.
Emese Kiss, Zénó Kuluncsics, Zoltán Kiss & Gyula Poór. (2010) Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody. Orvosi Hetilap 151:52, pages 2137-2144.
Crossref
Crossref
Ron J. Keizer, Alwin D.R. Huitema, Jan H.M. Schellens & Jos H. Beijnen. (2010) Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics 49:8, pages 493-507.
Crossref
Crossref
Peter Ruf, Michael Kluge, Michael Jäger, Alexander Burges, Constantin Volovat, Markus Maria Heiss, Jürgen Hess, Pauline Wimberger, Birgit Brandt & Horst Lindhofer. (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. British Journal of Clinical Pharmacology 69:6, pages 617-625.
Crossref
Crossref
Fernando de Mora & Rosa Torres. (2010) Biotechnology-Derived Medicines: What are They? A Pharmacological and a Historical Perspective. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 7:2, pages 145-157.
Crossref
Crossref
Akiko Ishii-Watabe, Yoshiro Saito, Takuo Suzuki, Minoru Tada, Maho Ukaji, Keiko Maekawa, Kouichi Kurose, Nahoko Kaniwa, Jun-ichi Sawada, Nana Kawasaki, Teruhide Yamaguchi, Takako Eguchi Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Teruhiko Yoshida, Takashi Ura, Miyuki Saito, Kei Muro, Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Nagahiro Saijo, Tetsuya Hamaguchi, Haruhiro Okuda & Yasuhiro Matsumura. (2010) Genetic Polymorphisme of FCGRT Encoding FcRn in a Japanese Population and Their Functional Analysis. Drug Metabolism and Pharmacokinetics 25:6, pages 578-587.
Crossref
Crossref
Gilles Paintaud. (2009) Pharmacocinétique des anticorps monoclonaux. médecine/sciences 25:12, pages 1057-1062.
Crossref
Crossref
Christopher R. Gibson, Punam Sandhu & William D. Hanley. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies
439
460
.
Roland E. Kontermann. (2009) Strategies to Extend Plasma Half-Lives of Recombinant Antibodies. BioDrugs 23:2, pages 93-109.
Crossref
Crossref
Jeffrey R. Chabot & Bruce Gomes. 2008. Drug Efficacy, Safety, and Biologics Discovery. Drug Efficacy, Safety, and Biologics Discovery
301
326
.
David Ternant, Alexandre Aubourg, Charlotte Magdelaine-Beuzelin, Danielle Degenne, Hervé Watier, Laurence Picon & Gilles Paintaud. (2008) Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients. Therapeutic Drug Monitoring 30:4, pages 523-529.
Crossref
Crossref
Jean Sibilia. (2007) Naissance et développement de l’immunothérapie ciblée : La révolution des biomédicaments. Revue du Rhumatisme 74, pages 42-51.
Crossref
Crossref
Gilles Paintaud, Dominique Tonelli, Eric Postaire, François Amalric, François Bassompierre, Laurent Becquemont, Guillaume Cartron, Dominic Cellier, Georges Dagher, Thierry Demerens, Alain Dessein, Danièle Girault, Jean-Marc Grognet, Vincent Le Gros, François Lemoine, Laurence Moachon, Marc Pallardy, Atul Pathak, Marc Peschanski, Lionel Ségard, Patrick Squiban, Daniel Vasmant, Luc Vermeesch, HervéWatier & Pierrette Zorzi. (2007) Biotherapies: Are they Just Like any Other Drugs?. Therapies 62:3, pages 235-239.
Crossref
Crossref
Gilles Paintaud, Dominique Tonelli, Eric Postaire, François Amalric, François Bassompierre, Laurent Becquemont, Guillaume Cartron, Dominic Cellier, Georges Dagher, Thierry Demerens, Alain Dessein, Danièle Girault, Jean-Marc Grognet, Vincent Le Gros, François Lemoine, Laurence Moachon, Marc Pallardy, Atul Pathak, Marc Peschanski, Lionel Ségard, Patrick Squiban, Daniel Vasmant, Luc Vermeesch, HervéWatier & Pierrette Zorzi. (2007) Biothérapies : des médicaments comme les autres ?. Therapies 62:3, pages 229-234.
Crossref
Crossref
Guillaume Cartron, Hélène Blasco, Gilles Paintaud, Hervé Watier & Chantal Le Guellec. (2007) Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. Critical Reviews in Oncology/Hematology 62:1, pages 43-52.
Crossref
Crossref
Jean Sibilia. (2006) Les bioth?rapies immunomodulatrices: Une r?volution th?rapeutique dans les maladies auto-immunes. Revue Francophone des Laboratoires 2006:384, pages 34-39.
Crossref
Crossref
Jean Sibilia. (2006) Bioth?rapies: ?volution ou r?volution?. La Presse M?dicale 35:4, pages 637-640.
Crossref
Crossref